{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:29:17Z","timestamp":1791116957595,"version":"4.1.0"},"reference-count":63,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,7,9]],"date-time":"2012-07-09T00:00:00Z","timestamp":1341792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The identification of variant Creutzfeldt\u2010Jakob disease (v<jats:styled-content style=\"fixed-case\">CJD<\/jats:styled-content>) in the <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content> in 1996 led to significant concerns about the possibility of secondary transmission, however the prevalence of subclinical v<jats:styled-content style=\"fixed-case\">CJD<\/jats:styled-content> and risks of v<jats:styled-content style=\"fixed-case\">CJD<\/jats:styled-content> transmission by plasma are not known. In the <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content>, public health precautions have been implemented in all recipients of coagulation factor concentrates manufactured from <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content> plasma pools between 1980 and 2001. The recent demonstration of abnormal prion protein in a spleen sample at autopsy of a <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content> haemophilic patient who received coagulation factor concentrates to which a donor incubating v<jats:styled-content style=\"fixed-case\">CJD<\/jats:styled-content> had contributed most likely represents the first case of v<jats:styled-content style=\"fixed-case\">CJD<\/jats:styled-content> transmission by coagulation factor concentrates. We review the uncertainties that surround risk of v<jats:styled-content style=\"fixed-case\">CJD<\/jats:styled-content> transmission by coagulation factor concentrates, the challenges in dealing with undefined risks, the rationale behind current policies and the implementation of v<jats:styled-content style=\"fixed-case\">CJD<\/jats:styled-content> surveillance and risk management measures in bleeding disorder patients in the <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2012.09201.x","type":"journal-article","created":{"date-parts":[[2012,7,9]],"date-time":"2012-07-09T06:41:16Z","timestamp":1341816076000},"page":"442-452","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Dealing with the uncertain risk of variant <scp>C<\/scp>reutzfeldt\u2010<scp>J<\/scp>akob disease transmission by coagulation replacement products"],"prefix":"10.1111","volume":"158","author":[{"given":"Carolyn M.","family":"Millar","sequence":"first","affiliation":[{"name":"Centre for Haematology Imperial College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Makris","sequence":"additional","affiliation":[{"name":"Department of Haematology Sheffield Haemophilia and Thrombosis Centre  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,9]]},"reference":[{"key":"e_1_2_16_2_1","volume-title":"Assessment to be carried out before surgery and\/or endoscopy to identify patients with, or at increased risk of, CJD or vCJD","author":"ACDP","year":"2011"},{"key":"e_1_2_16_3_1","volume-title":"Part 4 Infection control of CJD, vCJD and other human prion diseases in healthcare and community settings","author":"ACDP","year":"2011"},{"key":"e_1_2_16_4_1","volume-title":"Annexe F Endosopy","author":"ACDP","year":"2011"},{"key":"e_1_2_16_5_1","volume-title":"Analysis of the Risk of Variant Creutzfeldt\u2010Jakob Disease Transmssion by Medicinal Products of Human Origin and Labile Blood Products","author":"AFSSAPS","year":"2003"},{"key":"e_1_2_16_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70413-6"},{"key":"e_1_2_16_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-4-26"},{"key":"e_1_2_16_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02706-9"},{"key":"e_1_2_16_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38998408999.x"},{"key":"e_1_2_16_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39111169.x"},{"key":"e_1_2_16_11_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802695"},{"key":"e_1_2_16_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/39057"},{"key":"e_1_2_16_13_1","volume-title":"Management of possible exposure to CJD through medical procedures","author":"CJDIP","year":"2004"},{"key":"e_1_2_16_14_1","volume-title":"Assessment of exposure to particular batches of variant Creutzfeldt\u2010Jakob disease (vCJD) implicated plasma products","author":"CJDIP","year":"2004"},{"key":"e_1_2_16_15_1","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2004.0017"},{"key":"e_1_2_16_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b1442"},{"key":"e_1_2_16_17_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.24.1.519"},{"key":"e_1_2_16_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68930-7"},{"key":"e_1_2_16_19_1","volume-title":"Assessment of the risk of exposure to vCJD infectivity in blood and blood products","author":"Comer P.","year":"1999"},{"key":"e_1_2_16_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/385197a0"},{"key":"e_1_2_16_21_1","volume-title":"Position statement on new variant CJD and plasma\u2010derived medicinal products","author":"CPMP","year":"1998"},{"key":"e_1_2_16_22_1","volume-title":"Risk assessment for transmission of vCJD via Surgical Instruments: A modelling approach and numerical scenarios","author":"DH","year":"2001"},{"key":"e_1_2_16_23_1","volume-title":"Risk Assessment of Exposure to vCJD Infectivity in Blood and Blood Products","author":"DNV","year":"2003"},{"key":"e_1_2_16_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813342106"},{"key":"e_1_2_16_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62308-2"},{"key":"e_1_2_16_26_1","volume-title":"Draft quantitative risk assessment of vCJD risk potentially associated with the use of human plasma\u2010derived factor VIII manufactured under United States license from plasma collected in the US","author":"FDA","year":"2006"},{"key":"e_1_2_16_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.1999.009001003.x"},{"key":"e_1_2_16_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2000.7820086.x"},{"key":"e_1_2_16_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0042-9007.2004.00403.x"},{"key":"e_1_2_16_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015626"},{"key":"e_1_2_16_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)60744-1"},{"key":"e_1_2_16_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-3-4"},{"key":"e_1_2_16_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63105-7"},{"key":"e_1_2_16_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00833.x"},{"key":"e_1_2_16_35_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.18.10248"},{"key":"e_1_2_16_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1580"},{"key":"e_1_2_16_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.9.4649-4650.2002"},{"key":"e_1_2_16_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02719-7"},{"issue":"16","key":"e_1_2_16_39_1","first-page":"11","article-title":"New case of transfusion\u2010associated variant CJD","volume":"16","author":"HPA","year":"2006","journal-title":"The Communicable Disease Report Weekly"},{"key":"e_1_2_16_40_1","volume-title":"Health Protection Report","author":"HPA","year":"2011"},{"key":"e_1_2_16_41_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-83-11-2897"},{"key":"e_1_2_16_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61568-3"},{"key":"e_1_2_16_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15486-X"},{"key":"e_1_2_16_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2010.12.001"},{"key":"e_1_2_16_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02220.x"},{"key":"e_1_2_16_46_1","volume-title":"CJD Statistics","author":"NCJDSU","year":"2012"},{"key":"e_1_2_16_47_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi0615442"},{"key":"e_1_2_16_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16811-6"},{"key":"e_1_2_16_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02181.x"},{"key":"e_1_2_16_50_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2002.00211.x"},{"key":"e_1_2_16_51_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.26.15137"},{"key":"e_1_2_16_52_1","volume-title":"SEAC Epidemiology Subgroup position statement on the vCJD epidemic","author":"SEAC","year":"2006"},{"key":"e_1_2_16_53_1","volume-title":"Position statement on TSE infectivity in blood","author":"SEAC","year":"2006"},{"key":"e_1_2_16_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03989"},{"key":"e_1_2_16_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-6-5"},{"key":"e_1_2_16_56_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000084000.27403.15"},{"key":"e_1_2_16_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2005.11.007"},{"key":"e_1_2_16_58_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1997.00073.x"},{"key":"e_1_2_16_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05403-4"},{"key":"e_1_2_16_60_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2008.0069"},{"key":"e_1_2_16_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91412-9"},{"key":"e_1_2_16_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69835-8"},{"key":"e_1_2_16_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02508.x"},{"key":"e_1_2_16_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03402121"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2012.09201.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2012.09201.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T05:10:12Z","timestamp":1700543412000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2012.09201.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,9]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1111\/j.1365-2141.2012.09201.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09201.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,9]]},"assertion":[{"value":"2012-07-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}